English

设为首页 | 加入收藏 | 联系我们

首页 >> 研究生教育 >> 导师介绍 >> 博士生导师

刘艾林

时间:2020/7/17 来源: 阅读:27994次


刘艾林

刘艾林,女,博士,博士生导师, 研究员,PI。兼任世界中医药学会联合会网络药理学专业委员会理事,中国民族医药学会药理与毒理学分会理事,中国药理学会网络药理学专业委员会委员,中国补益药药理专业委员会委员,北京精神神经药理专业委员会委员,国内外若干核心期刊审稿专家,若干项目评审专家等社会职务。

 

联系方式:

E-mail: liuailin@imm.ac.cn,电话: 010-83150885

 

教育背景

2005年-2009年,澳门大学中华医药研究院,获生物医学博士学位

1992年-1995 年,南开大学化学系,获理学硕士学位

1985年-1989 年,厦门大学化学系,获理学学士学位

 

工作经历

2018-2019年,Purdue University in USA, 访问学者

1995年至今,中国医学科学院药物研究所,助理研究员、副研究员、研究员

1989-1992年,山东鲁抗制药集团,助理工程师

 

研究领域

1、计算药理学,网络药理学,药物信息学,虚拟筛选与新药发现

2、防治神经退行性疾病新药发现与机制研究

3、抗感染新药发现与机制研究

 

 

研究经历

1995年就职于中国医学科学院北京协和医学院药物研究所,主要从事药物发现,计算药理学,神经和感染药理学的科研与教学工作。1998-2000年参与筹建了国家药物筛选中心,建立了药物筛选信息化管理体系,包括样品信息的现代化管理系统、药学科学数据中心的建设、虚拟药物筛选与理性药物发现,系统地建立了神经退行性疾病-阿尔茨海默病相关药物筛选模型,抗感染性疾病-流感相关药物筛选模型,以及抗新型冠状病毒的药物发现研究,经大规模化合物的理性筛选与新药发现,发现了一些活性化合物。

参与完成了抗脑缺血1.1类化药匹诺塞林、抗帕金森病1.1类新药百可利以及治疗糖尿病神经病变的1.2类化药丹酚酸A3个新药的研发。主持承担了抗阿尔茨海默病新药DL0410的临床前研究,已完成其合成工艺的中试放大、晶型制备、药效药理、药代动力学、制剂处方、安全评价等各项研究。目前正在开展的研究还有天然产物来源抗感染创新药物研发关键技术研究,基于宿主蛋白的抗感染药物发现研究,以及抗神经退行性疾病药物发现研究。

主持承担重大新药创制专项、国家自然科学基金等等项目10余项,参与国家级项目30余项。近十年发表研究论文100余篇,申请专利20余项。获奖项目高通量药物筛选技术体系研究和应用新型高通量药物筛选用蛋白质芯片技术的研究与应用分别于2002年和 2011年获北京市科学技术二等奖,高通量药物筛选技术体系研究和应用天然产物的生物活性评价研究天然产物成药性评价技术创新及应用分别于2002年、2011年和2018年获得中华医学科技奖三等奖。

从事药学科研和教学工作二十余年,培养硕、博士研究生数十名;参与编写《迈向药物创新之路—“1035工程实施回顾》、《天然小分子药物》、《中药材古今研究概评》、《Natural Small Molecule Drugs from Plants》、《Dietary Phytochemicals and Microbes》、《高通量药物筛选》、《实验药理学》、《新药研究与评价概论》等专著18部,获优秀指导教师等个人荣誉奖多项。

 

发表论文

抗感染药物相关研究

1Xu L#, Jiang W#, Jia H, Zheng L, Xing J, Liu A*, Du G*. Discovery of Multitarget-Directed Ligands Against Influenza A Virus From Compound Yizhihao Through a Predictive System for Compound-Protein Interactions. Front Cell Infect Microbiol. 2020 Feb 11;10:16. doi: 10.3389/fcimb.2020.00016.

2、 Lin D, Yi YJ, Xiao MW, Chen J, Ye J, Hu AX*, Lian WW, Liu AL*, Du GH. Design, synthesis and biological evaluation of honokiol derivatives as influenza neuraminidase inhibitors. J Asian Nat Prod Res. 2019, 21(11): 1052–1067.

3、 Chen A, Liang Y, Ye J, Hu A*, Lian W, Liu A*, Du G. Synthesis of Chalcone Derivatives Containing Furan or/and Pyran Ring as Neuraminidase Inhibitors. Chem Res Chinese Universities, 2019, 35(3):395-402.

4、 Li C, Xu LJ, Lian WW, Pang XC, Jia H, Liu AL*, Du GH*. Anti-influenza effect and action mechanisms of the chemical constituent gallocatechin-7-gallate from Pithecellobium clypearia Benth. Acta Pharmacol Sin. 2018 Dec; 39(12):1913-1922.

5、 Liu J*#, Zu M#, Chen K, Gao L, Min H, Zhuo W, Chen W, Liu A*. Screening of neuraminidase inhibitory activities of some medicinal plants traditionally used in Lingnan Chinese medicines. BMC Complement Altern Med. 2018, 18(1):102. doi: 10.1186/s12906-018-2173-1.

6、 Zhang W, Xue W, Jia Y, Wen G, Lian X, Shen J, Liu A and Wu S*. A concise synthesis of (±)-7-O-galloyltricetiflavan. RSC Advances, 2018, 8: 14389-14392.

7、 Liu J*, Zu M, Chen K, Gao L, Min H, Zhou W, Chen W, and Liu A*. Screening of neuraminidase inhibitory activities of some medicinal plants traditionally used in Lingnan Chinese medicines. BMC Complementary and Alternative Medicine, 2018, 18:102. https://doi.org/10.1186/ s12906-018-2173-1.

8、 He Z#, Lian W#, Liu J*, Zheng R, Xu H, Du G, Liu A*. Isolation, structural characterization and neuraminidase inhibitory activities of polyphenolic constituents from Flos caryophylli. Phytochemistry Letters, 2017, 19:160-167.

9、 Fang Y, Xiao M, Hu A * Ye J, Lian W, Liu A *. Design, Synthesis, and Evaluation of 3-((4-(t-Butyl)-2-(2-benzylidenehydrazinyl) thiazol-5- yl)methyl)quinolin- 2(1H)-ones as Neuraminidase Inhibitors. Chinese J Chem, 2016, 34: 403-411.

10、         Li C, Song X, Song J, Pang X, Wang Z, Zhang Y, Lian W, Liu A*, Du G*. Pharmacokinetic study of gallocatechin-7-gallate from Pithecellobiumclypearia Benth. in rats. Acta Pharmaceutica Sinica B, 2016, 6(1): 64-70.

11、         Lian W, Fang J, Li C, Pang X, Liu AL*, Du GH*. Discovery of Influenza A virus neuraminidase inhibitors using support vector machine and Naïve Bayesian models. Mol Divers, 2016, 20(2):439-51.

12、         Yang XY, Liu AL, Liu SJ, Xu XW, Huang LF. Screening for Neuraminidase Inhibitory Activity in Traditional Chinese Medicines Used to Treat Influenza. Molecules, 2016, 21(9): 1138. doi: 10.3390.

13、         Zu M#, Li C#, Fang JS, Lian WW, Liu AL*, Zheng LS*, Du GH*. Drug discovery of host CLK1 inhibitors for influenza treatment. Molecules, 2015, 20, 19735–19747.

14、         Li C, Song X, Song J, Pang X, Wang Z, Zhang Y, Lian W, Liu A*, Du G*. Pharmacokinetic study of gallocatechin-7-gallate from Pithecellobium clypearia Benth. in rats. Acta Pharmaceutica Sinica B, 2016, 6(1): 64-70.

15、         Lian W, Fang J, Li C, Pang X, Liu AL*, Du GH*. Discovery of Influenza A virus neuraminidase inhibitors using support vector machine and Naïve Bayesian models. Mol Divers, 2015, DOI 10.1007/s11030-015-9641-z.

16、         Li C, Fang JS, Lian WW, Pang XC, Liu AL*, Du GH*. In vitro Antiviral Effects and 3D QSAR Study of Resveratrol Derivatives as Potent Inhibitors of Influenza H1N1 Neuraminidase. Chem Biol Drug Des. 2015, 85(4):427-38.

17、         Kang J, Liu C, Wang H, Li B, Li C, Chen R* and Liu A*. Studies on the Bioactive Flavonoids Isolated from Pithecellobium clypearia Benth. Molecules 2014, 19: 4479-4490.

18、         Dou J, Shi L, Hu A*, Dong M, Xu J, Liu A, Jiang Y. Synthesis and evaluation of 2-(2 -arylmorpholino)ethyl esters of ibuprofen hydrochlorides as COX-2 and serotonin reuptake inhibitors. Arch Pharm (Weinheim). 2014, 347(2):89-95.

19、         Li W, Xia L, Hu A*, Liu A*, Peng J, Tan W. Design and synthesis of 4-alkyl-2-amino (acetamino)-6-aryl-1,3-thiazine derivatives as influenza neuraminidase inhibitors. Arch Pharm (Weinheim). 2013, 346(9):635-44.

20、         Zu M, Yang F, Zhou W, Liu A*, Du G*, Zheng L*. In vitro anti-influenza virus and anti-inflammatory activities of theaflavin derivatives. Antiviral Res. 2012, 94: 217-224.

21、         Yang F, Zhou WL, Liu AL*, Qin HL, Lee SM, Wang YT, Du GH*. The Protective Effect of 3-Deoxysappanchalcone on In Vitro Influenza Virus-induced Apoptosis and Inflammation. Planta Med. 2012, 78:968-973.

22、         Zhan P, Wang L, Liu H, Chen X, Li X, Jiang X, Zhang Q, Liu X, Pannecouque C, Naesens L, De Clercq E, Liu A, Du G. Arylazolyl (azinyl)thioacetanilide. Part 9: Synthesis and biological investigation of thiazolylthioacetamides derivatives as a novel class of potential antiviral agents. Arch Pharm Res. 2012, 35(6):975-86.

23、         Liu B, Deng AJ, Yu JQ, Liu AL, Du GH, Qin HL. Chemical constituents of the whole plant of Elsholtzia rugulosa. J Asian Nat Prod Res. 2012, 14(2):89-96.

24、         Li Z, Zhan P, Naesens L, Vanderlinden E, Liu A, Du G, De Clercq E, Liu X. Synthesis and Preliminary Biologic Evaluation of 5-Substituted-2-(4-substituted phenyl)-1,3-Benzoxazoles as A Novel Class of Influenza Virus A Inhibitors. Chem Biol Drug Des. 2012, 79(6):1018-24.

25、         Gao L, Zu M, Wu S, Liu AL*, Du GH*. 3D QSAR and docking study of flavone derivatives as potent inhibitors of influenza H1N1 virus neuraminidase. Bioorganic & Medicinal Chemistry Letters, 2011, 21: 5964–5970.

26、         Yu M, Liu A, Du G, Naesens L, Vanderlinden E, De Clercq E, Liu X. Discovery of dihydro-alkyloxy-benzyl-oxopyrimidines as promising anti-influenza virus agents. Chem Biol Drug Des. 2011, 78(4):596-602.

27、         Liu Y, Zhang L, Gong J, Fang H, Liu A, Du G, Xu W. Design, synthesis, and biological activity of thiazole derivatives as novel influenza neuraminidase inhibitors. J Enzyme Inhib Med Chem. 2011, 26(4):506-13.

28、         Zhang L, Cheng YX, Liu AL, Wang HD, Wang YL, Du GH*. Antioxidant, Anti-Inflammatory and Anti-Influenza Properties of Components from Chaenomeles speciosa. Molecules. 2010, 15(11): 8507-8517.

29、         Liu AL, Yang F, Zu M, Zhou D, Lee SM, Wang YT, Du GH. In Vitro anti-influenza viral activities of stilbenoids from the Lianas of Gnetum pendulum. Planta Med, 2010, 76: 1874-1876.

30、         Liu AL, Shu SH, Qin HL, Lee SM, Wang YT, Du GH. In vitro anti-influenza viral activities of constituents from Caesalpinia sappan. Planta Medica, 2009, 75(4): 337-339.

31、         Liu AL, Liu B, Qin HL, Lee SM, Wang YTDu GH. Anti-influenza Virus Activities of Flavonoids from the Medicinal Plant Elsholtzia rugulosa. Planta Medica, 2008, 74: 746-51.

32、         Liu AL, Wang HD, Lee SM, Wang YT, Du GH. Structure-activity relationship of flavonoids as influenza virus neuraminidase inhibitors and their in vitro anti-viral activities. Bioorganic & Medicinal Chemistry, 2008, 16: 7141-7147.

33、         Liu AL, Lee SMY, Wang YT, Du GH. Elsholtzia: Review of traditional uses, chemistry and pharmacology. Jouranl of Chinese Pharmaceutical Sciences, 2007, 16(2):73-78.

34、         Liu AL, Wang, YT, Du, GH. Neuraminidase as a target for drugs for the treatment of influenza. Drugs Fut 2005, 30(8): 799-806.

35、         Liu AL, Cao HP, Du GH. Drug Screening for Influenza Neuraminidase Inhibitors. Science in China Ser C, 2005, 48(1):1-5.

36、         Zhang J, Wang Q, Fang H, Xu W*, Liu A, Du G. Design, synthesis, inhibitory activity, and SAR studies of hydrophobic p-aminosalicylic acid derivatives as neuraminidase inhibitors. Bioorg Med Chem. 2008; 16(7): 3839-47.

37、         Zhang J, Xu W*, Liu A, Du G. Design, synthesis, and preliminary evaluation of new pyrrolidine derivatives as neuraminidase inhibitors. Med Chem. 2008; 4(3): 206-9.

38、         Zhang J, Wang Q, Fang H, Xu WF*, Liu AL, Du GH. Design, synthesis, inhibitory activity, and SAR studies of pyrrolidine derivatives as neuraminidase inhibitors. Bioorg. Med. Chem. 2007, 15, 8286–8294.

39、         刘艾林*,杜冠华*。基于靶点的抗新型冠状病毒病 COVID-19 药物发现。药学学报,2020556):1073-1080

40、         郭鹏飞,方坚松,刘艾林*。基于网络药理学的生脉散用于 COVID-19 恢复期治疗的物质基础。世界中医药,20201512):1669-1681

41、         梅,贺超凡,刘 玲,叶 * 胡艾希*,陈 云,许律捷,刘艾林。1, 2, 4-三唑-3-硫醚衍生物的合成、晶体结构与神经氨酸酶抑制活性。有机化学,2020http://kns.cnki.net/kcms/detail/31.1321.o6.20200527.1730.005.html

42、         许律捷,姜雯,庞晓丛,康德,熊婉迪,刘睿,邢建国,刘艾林*,杜冠华。复方一枝蒿抗流感有效成分的网络药理学研究。药学学报,2017,525):745-752

43、         曹雨,李金花,刘海波,刘艾林,张翔,顾健,黄林芳*。隔山消抗神经氨酸酶活性及化学成分研究。 中草药,201748(21): 4485-4492

44、         连雯雯,刘艾林*,杜冠华*。流感病毒RNA 聚合酶PA 亚基: 潜在抗流感药物靶点。中国药理学通报,201531(3)297-302

45、         李超,祖勉,连雯雯,刘艾林*,杜冠华*。重组人CLK1的真核表达及鉴定。生物技术通讯,2014254):455-459

46、         孙兰,刘艾林,王振中*,毕宇安,杜冠华,萧伟*。热毒宁注射液及其组分对流感病毒神经氨酸酶的抑制作用研究。现代药物与临床。201429(1): 27-31.

47、         周伟玲, 杨帆, 祖勉, 李超, 刘艾林*, 杜冠华。流感病毒核酸内切酶抑制剂高通量筛选模型的建立。中国新药杂志,20132210):11371142

48、         王冬梅,刘艾,黄林芳*,陈士林。鸡屎藤抑制丁酰胆碱酯酶活性及活性部位的UPLC-QTOF分析。中国药科大学学报, 201344(01): 44-48

49、         陈考坛,周伟玲,刘嘉炜,祖勉,何紫凝,杜冠华,陈蔚文,刘艾林*。虎杖抗H1N1流感病毒神经氨酸酶活性成分研究。中国中药杂志,20123720):3068-73

50、         杨帆,刘艾林,杜冠华。流感病毒神经氨酸酶抑制活性测定方法的标准研究。药学学报,201247(6): 730-733

51、         祖勉,周丹,高丽,刘艾林*,杜冠华。临床常用中成药的体外抗流感病毒活性评价。药学学报,2010453):408412

52、         杨帆,刘艾林,杜冠华。阿比朵尔药理作用与临床应用研究进展。中国药学杂志,2010452):9092

53、         刘艾林,王海娣,杨帆,杜冠华。抗流感神经氨酸酶抑制剂的研究进展。药物学报,200944: 935942

54、         王海娣,刘艾林*,杜冠华。黄酮类化合物神经氨酸酶抑制活性评价。中国新药杂志,20091815):55-59

55、         张杰,王强,徐文方,刘艾林,杜冠华。吡咯烷类神经氨酸酶抑制剂的设计、合成与初步活性研究。中国药学杂志, 200843(4)314-318

 

神经退行性疾病药物相关研究

1.      Zhou W, Lian WW, Yan R, Jia H, Xu LJ, Wang L, Liu AL*, Du GH*. DL0410 ameliorates cognitive deficits in APP/PS1 transgenic mice by promoting synaptic transmission and reducing neuronal loss. Acta Pharmacol Sin. 2020, 41(5):599-611.

2.      Zhang B, Zhao J, Wang Z, Xu L, Liu A*, Du G*. DL0410 attenuates oxidative stress and neuroinflammation via BDNF/TrkB/ERK/CREB and Nrf2/HO-1 activation. Int Immunopharmacol. 2020 Jul 6;86:106729. doi: 10.1016/j.intimp.2020.106729.

3.      Pang X, Zhao Y, Song J, Kang, Wu S, Wang L, Liu A*, Du G*. Pharmacokinetics, excretion and metabolites analysis of DL0410, a dual‑acting cholinesterase inhibitor and histamine‑3 receptor antagonist. Mol Med Rep. 2019, 20: 1103-1112.

4.      Pang X, Fu W, Wang J, Kang D, Xu L, Zhao Y, Liu AL*, Du GH*. Identification of estrogen receptor α antagonists from natural products By virtual screening approaches. Oxid Med Cell Longev. 2018, 2018:6040149. doi:10.1155/2018/6040149.

5.      Pang X#, Zhang B#, Mu G, Xia J, Xiang Q, Zhao X, Liu A*, Du G*, Cui Y*. Screening of cytochrome P450 3A4 inhibitors via in silico and in vitro approaches. RSC Adv, 2018, 8, 34783-34792.

6.      Pang XC, Kang D, Fang JS, Zhao Y, Xu VJ, Lian WW, Liu AL*, Du GH*. Network pharmacology-based analysis of Chinese herbal Naodesheng formula for application to Alzheimer’s Disease.  Chinese Journal of Natural Medicines, 2018, 16(1): 0053-0062.

7.      Wang DM, Feng B, Fu H, Liu AL, Wang L, Du GH, Wu S*. Design, Synthesis, and Biological Evaluation of a New Series of Biphenyl/Bibenzyl Derivatives Functioning as Dual Inhibitors of Acetylcholinesterase and Butyrylcholinesterase. Molecules, 2017, 22: 172; doi:10.3390.

8.      Lian W, Fang J, Xu L, Zhou W, Kang D, Xiong W, Jia H, Liu AL*, Du GH*. DL0410 Ameliorates Memory and Cognitive Impairments Induced by Scopolamine via Increasing Cholinergic Neurotransmission in Mice. Molecules. 2017, 22(3), 410. pii: E410.

9.      Lian W, Jia H, Xu L, Zhou W, Kang D, Liu A*, Du G*. Multi-Protection of DL0410 in Ameliorating Cognitive Defects in D-Galactose Induced Aging Mice. Front Aging Neurosci. 2017, 9:409. doi: 10.3389/fnagi.2017.00409.

10.   Fang J, Wang L, Li Y, Lian W, Pang X, Wang H, Yuan D, Wang Q*, Liu AL*, Du GH*. AlzhCPI: A knowledge base for predicting chemical-protein interactions towards Alzheimer's disease. PLoS One. 2017 May 25;12(5):e0178347. doi: 10.1371/journal.pone.0178347. eCollection 2017.

11.   Pang X, Wang L, Kang, Zhao Y, Wu S, Liu AL*, Du GH*. Effects of P-Glycoprotein on the Transport of DL0410, a Potential Multifunctional Anti-Alzheimer Agent. Molecules 2017, 22(8): 1246. doi: 10.3390/molecules22081246.

12.   Pang X, Fu H, Yang S, Wang L, Liu AL*, Wu S*, Du GH*. Evaluation of Novel Dual Acetyl- and Butyrylcholinesterase Inhibitors as Potential Anti-Alzheimer’s Disease Agents Using Pharmacophore, 3D-QSAR, and Molecular Docking Approaches. Molecules 2017, 22(8): 1254. doi: 10.3390/molecules22081254.

13.   Pang X, Zhao Y, Wang J, Zhou QM, Xu LJ, Kang D Zhou W, Liu AL*, Du GH*. The bioinformatic analysis of the dysregulated genes and microRNAs in entorhinal cortex, hippocampus and blood for Alzheimer’s disease. BioMed Research International. 2017.7.

14.   Fang J, Pang X, Yan R, Lian W, Li C, Wang Q, Liu AL *, and Du GH *. Discovery of Neuroprotective Compounds by Machine Learning Approaches. RSC Adv., 2016, 6: 9857-9871.

15.   Fang J, Pang X, Wu P, Yan R, Gao L, Li C, Lian W, Wang Q, Liu AL*, Du GH*. Molecular Modeling on Berberine Derivatives toward BuChE: An Integrated Study with Quantitative Structure–Activity Relationships Models, Molecular Docking, and Molecular Dynamics Simulations. Chem Biol Drug Des. 2016 May; 87(5):649-63.

16.   Zhou D, Zhou W, Song JK, Feng ZY, Yang RY, Wu S, Wang L, Liu AL*, Du GH*.DL0410, a novel dual cholinesterase inhibitor, protects mouse brains against A-β-induced neuronal damage via the Akt/JNK signaling pathway. Acta Pharmacol Sin.2016, 37(11):1401-1412.

17.   Fang J, Pang X, Yan R, Lian W, Li C, Wang Q, Liu AL*, Du GH*. Discovery of Neuroprotective Compounds by Machine Learning Approaches. RSC Adv., 2016, 6: 9857-9871.

18.   Fang J, Li Y, Liu R, Pang X, Li C, Yang R, He Y, Lian W, Liu AL*, Du GH*. Discovery of multitarget-directed ligands against Alzheimer's disease through systematic prediction of chemical-protein interactions. J Chem Inf Model. 2015, 55(1):149-64.

19.   Fang J, Pang X, Wu P, Yan R, Gao L, Li C, Lian W, Wang Q, Liu AL*, Du GH*. Molecular Modeling on Berberine Derivatives toward BuChE: An Integrated Study with Quantitative Structure–Activity Relationships Models, Molecular Docking, and Molecular Dynamics Simulations. Chem Biol Drug Des, 2015, doi: 10.1111/cbdd.12700.

20.   Gao L, Li C, Yang RY, Lian WW, Fang JS, Pang XC, Qin XM, Liu AL*, Du GH*. Ameliorative effects of baicalein in MPTP-induced mouse model of Parkinson's disease: A microarray study. Pharmacol Biochem Behav. 2015, 133: 155-163.

21.   Yang RY, Zhao G, Wang DM, Pang XC, Wang SB, Fang JS, Li C, Liu AL*, Wu S*, Du GH*. DL0410 can reverse cognitive impairment, synaptic loss and reduce plaque load in APP/PS1 transgenic mice. Pharmacol Biochem Behav. 2015, 139(Pt A):15-26.

22.   Gao L, Zhao G, Fang JS, Yuan TY, Liu AL*, Du GH*.. Discovery of the neuroprotective effects of alvespimycin by computational prioritization of potential anti-parkinson agents. FEBS Journal, 2014, 281:1110-1122.

23.   Fang J, Wu P, Yang R, Gao L, Li C, Wang D, Wu S, Liu AL*, Du GH*. Inhibition of acetylcholinesterase by two genistein derivatives: kinetic analysis, molecular docking and molecular dynamics simulation. Acta Pharmaceutica Sinica B, 2014, 4(6):430–437.

24.   Fang J, Yang R, Gao L, Yang S, Pang X, Li C, He Y, Liu AL*, Du GH*. Consensus models for CDK5 inhibitors in silico and their application to inhibitor discovery. Mol Divers. 2015, 19(1):149-62.

25.   Fang J, Yang R, Gao L, Zhou D, Yang S, Liu AL*, Du GH*. Predictions of BuChE Inhibitors Using Support Vector Machine and Naive Bayesian Classification Techniques in Drug Discovery. J Chem Inf Model. 2013, 53(11):3009-20.

26.   Gao L, Fang JS, Bai XY, Zhou D, Wang YT, Liu AL*, Du GH*. In silico Target Fishing for the Potential Targets and Molecular Mechanisms of Baicalein as an Antiparkinsonian Agent: Discovery of the Protective Effects on NMDA Receptor-Mediated Neurotoxicity. Chem Biol Drug Des. 2013, 81(6):675-87.

27.   Gao L, Zhao G, Fang JS, Yuan TY, Liu AL*, Du GH*. Discovery of the neuroprotective effects of alvespimycin by computational prioritisation of potential anti-parkinson agents. FEBS J. 2013, doi: 10.1111/febs.12672.

28.   Lam IK, Alex D, Wang YH, Liu P, Liu AL, Du GH and Lee SM*. In vitro and in vivo structure and activity relationship analysis of polymethoxylated flavonoids: identifying sinensetin as a novel anti-angiogenesis agent. Molecular Nutrition and Food Research, 2012 56(6):945-56.

29.   Liu R, Meng F, Zhang L, Liu A, Qin H, Lan X, Li L, Du G. Luteolin isolated from the medicinal plant Elsholtzia rugulosa (Labiatae) prevents copper-mediated toxicity in β-amyloid precursor protein Swedish mutation overexpressing SH-SY5Y cells. Molecules. 2011, 16(3):2084-96.

30.   Liu AL, Guang HM, Zhu LY, Du GH, Lee SMY, Wang YT. 3D-QSAR analysis of a new type of Acetylcholinesterase Inhibitors. Science in China Ser C, 2007, 50(6):726-30.

31.   郑一夫#,孔令雷#,贾皓,张宝月,王喆,许律捷,刘艾林*,杜冠华* 基于系统的化合物-靶点相互作用预测模型的消栓通络方抗脑卒中网络药理学研究。药学学报,202055(2): 256 −264

32.   张宝月,庞晓丛,贾皓,王喆,刘艾林* 杜冠华*。基于全球上市药物数据的抗阿尔茨海默病重定位新药发现。药学学报,2019547):1214-1224.

33.   张宝月,刘艾林*,杜冠华*。能量代谢紊乱对疾病的影响及其潜在药物靶点。药学学报,2019548):1372-1381.

34.   贾皓,庞晓丛,赵赢,王海港,刘艾林*,杜冠华*。远志治疗阿尔茨海默病的网络药理学作用机制。中国新药杂志,2018,27(04)398-404

35.   #,冯章英#,周 围,庞晓丛,连雯雯,吴 松,刘艾林*,杜冠华* 异黄酮衍生物J39136对东莨菪碱致学习记忆障碍模型小鼠的影响。中国新药杂志,201726(10):110-114

36.   庞晓丛,王喆,方坚松, 连雯雯, 赵嬴, 康德, 刘艾林*, 杜冠华*。治疗阿尔茨海默病的中药有效成分的网络药理学研究。药学学报,2016515):725-731

37.   王增绘,王冬梅,刘艾林,黄林芳*. 山豆根抑制乙酰胆碱酯酶活性剂活性部位UPLC-TOF-MS分析. 中国现代中药 2015 17(9),912-916

38.   冯章英,宋俊科,黄超,刘艾林*,杜冠华*。新型胆碱酯酶抑制剂J39136 大鼠体内血药浓度测定方法的建立及组织分布研究。中国新药杂志,2014237):24-29

39.   杨然耀,方坚松,周丹,刘艾林*,杜冠华*Cdk5/p35抑制剂高通量筛选方法的建立及应用。中国新药杂志,2014237):30-35

40.   冯章英,周丹,杨然耀,刘艾林*,杜冠华。 乙酰胆碱酯酶抑制剂高通量筛选方法的优化及应用。中国新药杂志,20132211):1520

41.   冯章英,刘艾林* ,杜冠华。γ分泌酶调节剂的研究现状。中国药学杂志,2012 4718):1525-1530

42.   高梅,刘艾林,杜冠华。丁酰胆碱酯酶抑制剂的高通量筛选.中国新药杂志,20091812):1145-1148

 

抗肿瘤等疾病药物相关研究

1.      Pang X, Zhao Y, Wang J, Li W, Xiang Q, Zhang Z, Wu S, Liu AL*, Cui YM* and Du GH*. Competing endogenous RNA and co-expression network analysis for identification of potential biomarkers and therapeutics in association with metastasis risk and progression of prostate cancer. Oxidative Medicine and Cellular Longevity, Volume 2019, Article ID 8265958, 21 pages https://doi.org/10.1155/2019/8265958.

2.      Zhang BY, Zheng YF, Pang XC, Wang Z, Ding H, Liu AL*. Network Pharmacology‑based Study of the Active Constituents of Chinese Medicinal Formulae for Antitumor Mechanism. World J Tradit Chin Med, 2018, 4(2):43-53.

3.      Kang D, Pang X, Lian W, Xu L, Wang,J, Jia H, Zhang B, Liu AL*, Du GH*. Discovery of VEGFR2 inhibitors by integrating naıve Bayesian classification, molecular docking and drug screening approaches. RSC Advances, 2018, 8: 5286- 5297.

4.      Wang L, Pang XC, Yu ZR, Yang SQ, Liu AL, Wang JH*, Du GH*. Actinomycin D synergistically enhances the cytotoxicity of CDDP on KB cells by activating P53 via decreasing P53–MDM2 complex. Journal of Asian Natural Products Research, 2017, 19(6): 630–643.

5.      Cai WX, Liu AL, Li ZM, Dong WL *, Liu XH * and Sun NB. Synthesis and Anticancer Activity of Novel Thiazole-5-Carboxamide Derivatives. Applied Sciences, 2016, 6(1), 8 -17.

6.      Cui G, Chen H, Cui W, Guo X, Fang J, Liu A, Chen Y, Lee SM*. FGF2 Prevents Sunitinib-Induced Cardiotoxicity in Zebrafish and Cardiomyoblast H9c2 Cells. Cardiovasc Toxicol. 2016, 16(1):46-53.

7.      Cui G, Chen H, Cui W, Guo X, Fang J, Liu A, Chen Y, Lee SM*. FGF2 Prevents Sunitinib-Induced Cardiotoxicity in Zebrafish and Cardiomyoblast H9c2 Cells. Cardiovasc Toxicol. 2016, 16(1):46-53.

8.      Huang F, Li S, Lu X, Liu A, Du G, Shi G. Two glutathione S-transferase inhibitors from Radix Angelicae sinensis. Phytother Res. 2011, 25(2):284-9.

9.      Gong LL, Fang LH, Peng JH, Liu AL, Du GH. Integration of virtual screening with high-throughput screening for the identification of novel Rho-kinase I inhibitors. J Biotechnol. 2010, 145(3):295-303.

10.   Zhou Y, Liu A, Wang W, Du G. Using the protein chip to screen agonists and antagonists of the androgen receptor. J Biomol Screen. 2008; 13(4): 276-84.

11.   Wang P, Liu AL, Li ZH, Du GH, Qin HL. Stemoninine-type alkaloids from the roots of Stemona sessilifolia. J Asian Nat Prod Res. 2008; 10(4): 311-4.

12.   Wang P, Liu AL, An Z, Li ZH, Du GH, Qin HL. Novel alkaloids from the roots of stemona sessilifolia. Chemistry & Biodiversity, 2007, 4:523-30.

13.   Wu L, Liu AL, Lu Y, Du GH. 2,7-Diacetyxanthene. Acta Crystallographica E. 2006. E62:o1770-1.

14.   张宝月,郑一夫,庞晓丛,郑湘锦,王喆,丁虹,刘艾林*,杜冠华*。中药抗肿瘤作用的物质基础与网络机制研究。世界中医药,2018138):1997-2009

15.   许律捷,康德,贾皓,王金华,徐亚娟,张国印,杜新磊,刘艾林*,杜冠华*。二仙膏对环磷酰胺致白细胞减少症小鼠免疫功能的影响与免疫的初步研究。中国新药杂志,2018, 278):102-109

16.   刘艾林,张莉,杜冠华*。闹羊花毒之历史认识与评价。中药药理与临床,2018345):161-163

17.   雷甜甜,刘艾林*,杜冠华*。欧美上市药物信息权威发布数据库及其应用。中国新药杂志,20182716):1825-1829

18.   韩露,程肖蕊,伯晓晨,曹亮,陈纯,陈洛南,陈禹保,段大跃,方坚松,高丽,高莉,高耀,李美娜,李学军,刘艾林,刘骏,秦雪梅,Bauer RUDOLF,宋文婷,Alastair STEWART,孙蓉,孙妩弋,田俊生,王永华,王忠,魏伟,肖伟,徐峰,徐筱杰,张文娟,张媛媛,赵静,周文霞,张永祥. 新形势新策略——网络药理学与中药新药研发. 中国药理学与毒理学杂志, 2018, 32 (11): 827-875.

19.   赵赢,刘艾林,杜冠华。中国与美国罕见病药物政策对比分析。中国新药杂志,2016251):31-3549

20.   蔡文玺,王润玲,董卫莉*刘艾林*。新型含吡啶基吡唑酰胺类化合物的合成与抗肿瘤活性。天津医科大学学报,2016222):115-118.

21.   刘明,刘阳,刘艾林,张冬凯,陈明桂,吴长春,华学文,周莎,李正名*。含亚磺酸酯或亚磺酰胺基团的香豆素衍生物的合成及生物活性研究。有机化学,2016361653-1661.

22.    庞晓从,康德,刘艾林*,杜冠华。中日药品数据保护制度的比较研究。中国药物评价,2016331):47-50

23.   生立嵩,刘艾林,杜冠华*。中国-加拿大医药卫生领域纳米技术政策比较研究。中国药物评价,2016332):111-113

24.   方坚松,刘艾林*,杜冠华*。基于化学信息学方法预测药物靶点的研究进展。药学学报,2014,4910):1357-64

25.   庞晓丛,刘艾林*,杜冠华。药物靶点数据库的应用进展。中国药学杂志,20154922):1969-1972.

26.   赵瑞,方坚松,刘艾林,杜冠华*。虚拟筛选技术辅助SERT 抑制剂高通量筛选模型的建立及应用。药学学报,2015,509):1116-1121

27.   周围,刘艾林*,杜冠华。中国与英国药品不良反应监测制度的对比研究。中国药物评价,2015326):376--380

28.   李婉,胡艾希*刘艾林*彭俊梅,夏 林,谭卫清4-烷基-6-芳基-1,3-噻嗪的合成与生物活性。有机化学,2013331478-1482

29.   李超,刘艾林*,杜冠华*。天然异黄酮类化合物的药理学研究进展。中国新药杂志,20132212):1415-1420

30.   高丽,刘艾林*,杜冠华。新分子实体与新药研发。中国药学杂志,201247(21): 1770-1772

31.   高丽,刘艾林*,杜冠华。计算机辅助药物设计在新药研发中的应用进展。中国药学杂志,2011469):641645

32.   周丹,刘艾林*,杜冠华。迷迭香酸的药理学研究进展。中国新药杂志,2011207):594-598

33.   祖勉,刘艾林*,杜冠华*。茶黄素及其衍生物药理作用研究进展。中国药学杂志,2011 4620):15371541

34.   刘艾林,杜冠华*。网络药理学:药物发现的新思想。药学学报,20104512):14721477

35.   杨帆,刘艾林*,杜冠华。黄酮类化合物对肿瘤多药耐药调节作用的研究进展。中国新药杂志。201019(2) 109113

36.   刘艾林,杜冠华。虚拟筛选辅助新药发现的研究进展。药学学报,2009446):566570

37.   刘莹,李喜凤,刘艾林,李志宏,杜冠华,秦海林。细皱香薷叶的化学成分研究。中草药,2009 409 ):13561359

38.   王海娣,刘艾林*,杜冠华. 芹菜素的药理作用研究新进展。中国新药杂志. 20081718):5-9

39.   刘艾林,李铭源,王一涛,杜冠华。丹参药理学活性物质基础研究现状。中国药学杂志, 2007 42: 641-6.

40.   黄锋,林黎琳,胡娟娟,刘艾林,肖培根,杜冠华。黄花倒水莲抗氧化活性研究。中国天然产物,20064:291-294

 

参与编写专著

1、桑国卫,陈传宏,陈凯先。 《迈向药物创新之路—“1035工程实施回顾》。北京:高等教育出版社,2019年。

2、 杜冠华。《中药材古今研究概评》。北京:中国医药科技出出版社,2019年。

3、 杜冠华。《天然小分子药物》。北京:人民卫生出版社,2018年。

4、 Du GH. Natural Small Molecule Drugs from Plants. Springer, 2018.

5、李晓辉等。《新药研究与评价概论》,北京:人民卫生出版社,2014

6、艾铁民。《中国药用植物志》第十二卷,北京:北京大学医不出版社,2013年。

7Patra A.K. (ed.) Dietary Phytochemicals and Microbes. 93-126, Springer sciences, Business Media Dordrecht, 2012.

8、再帕尔.阿不力孜。《天然产物研究方法和技术》,北京:化学工业出版社,2010年。

9、刘丽华。《医药卫生领域标准规范资料汇编》,北京:中国协和医科大学出版社,2010年。

10、杜冠华。《药理学原理》,北京:人民卫生出版社,2009年。

11、《新药发现寻找维护人类健康的武器》,北京:中国科学技术出版社,2009年。

12、杜冠华。《药物与营养物质的相互作用》,北京:人民卫生出版社,2008年。

13、张均田,杜冠华。《丹参大全-丹参药理学》,人民卫生出版社,2008年。

14、《药物发现》,北京:科学出版社,2007年。

15、王德心。《组合化学原理、技术及应用》, 北京:中国协和医科大学出版社, 2005年。

16、甄永苏。《抗肿瘤药物研究与开发》,北京:化学工业出版社,2004年。

17、杜冠华。《实验药理学》,北京:中国协和医科大学出版社, 2004年。

18、杜冠华。《高通量药物筛选》,北京:化学工业出版社,2002年。

 

授权专利:

1、对乙、丁酰胆碱酯酶具有双重抑制活性的化合物及其用途。专利号:ZL 200710107604.6.

2、作为肝X受体调节剂的化合物。专利号:ZL 200810102538.8.

3、4-烷基-6-芳基-34-二氢嘧啶-2-硫酮的制备及其作为抗抑郁药物的应用。专利号:ZL 201210198757.7.

4、3-[[2-(2-苄亚肼基)噻唑-5-]喹啉-21H)-酮及其制备与应用。专利号:ZL 201410017103.9.

5、黄连碱衍生物、其合成方法及其抗肿瘤的药物用途。ZL 201210411739.2.

6、一个异黄酮衍生物的多靶点作用及其改善学习记忆用途。ZL 201310113150.9.

内部链接
相关链接